EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial

Thomas Seufferlein, Ludwig Lausser, Alexander Stein, Dirk Arnold, Gerald Prager, Stefan Kasper-Virchow iD, Michael Niedermeier, Lothar Müller, Stefan Kubicka, Alexander König, Petra Büchner-Steudel, Kai Wille und 7 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0304324 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Thomas Seufferlein und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Bevacizumab, Leucovorin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi Genzyme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies (mAbs) are widely used for tumor treatment, including metastatic colorectal cancer (mCRC). So far, there are no biomarkers that reliably predict resistance to anti-VEGF mAbs like bevacizumab. A biomarker-guided strategy for early and accurate assessment of resistance could avoid the use of non-effective treatment and improve patient outcomes. We hypothesized that repeated analysis of multiple cytokines and angiogenic growth factors (CAFs) before and during treatment using machine learning could provide an accurate and earlier, i.e., 100 days before conventional radiologic staging, prediction of resistance to first-line mCRC treatment with FOLFOX plus bevacizumab. Patients and methods 15 German and Austrian centers prospectively recruited 50 mCRC patients receiving FOLFOX plus bevacizumab as first-line treatment. Plasma samples were collected every two weeks until radiologic progression (RECIST 1.1) as determined by CT scans performed every 2 months. 102 pre-selected CAFs were centrally analyzed using a cytokine multiplex assay (Luminex, Myriad RBM).

Results

Using random forests, we developed a predictive machine learning model that discriminated between the situations of “no progress within 100 days before radiological progress” and “progress within 100 days before radiological progress”. We could further identify a combination of ten out of the 102 CAF markers, which fulfilled this task with 78.2% accuracy, 71.8% sensitivity, and 82.5% specificity.

Conclusions

We identified a CAF marker combination that indicates treatment resistance to FOLFOX plus bevacizumab in patients with mCRC within 100 days prior to radiologic progress.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBevacizumabLeucovorinAntineoplastic Combined Chemotherapy ProtocolsOrganoplatinum CompoundsFluorouracilDrug Resistance, NeoplasmHumansFemaleMaleMiddle AgedAgedProspective StudiesAdultNeoplasm MetastasisBiomarkers, Tumor

Substanzen

BevacizumabLeucovorinOrganoplatinum CompoundsFluorouracilBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
  • Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
  • Faculty of Computer Science, Technische Hochschule Ingolstadt, Ingolstadt, Germany.
  • Hematology-Oncology Practice Eppendorf, University Cancer Center Hamburg, Hamburg, Germany.
  • Asklepios Cancer Center Hamburg, AK Altona, Hamburg, Germany.
  • Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Stefan Kasper-Virchow, Hans A Kestler

Förderung

  • Sanofi Genzyme

Zitieren

APA

Seufferlein, T., Lausser, L., Stein, A., Arnold, D., Prager, G., Kasper-Virchow, S., Niedermeier, M., Müller, L., Kubicka, S., König, A., Büchner-Steudel, P., Wille, K., Berger, A. W., Kestler, A. M. R., Kraus, J. M., Werle, S. D., Perkhofer, L., Ettrich, T. J., & Kestler, H. A. (2024). Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0304324

Vancouver

Seufferlein T, Lausser L, Stein A, Arnold D, Prager G, Kasper-Virchow S, et al. Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial. PLOS ONE. 2024. doi:10.1371/journal.pone.0304324

BibTeX
@article{Seufferlein2024,
  author = {Seufferlein, Thomas and Lausser, Ludwig and Stein, Alexander and Arnold, Dirk and Prager, Gerald and Kasper-Virchow, Stefan and Niedermeier, Michael and Müller, Lothar and Kubicka, Stefan and König, Alexander and Büchner-Steudel, Petra and Wille, Kai and Berger, Andreas W and Kestler, Angelika M R and Kraus, Johann M and Werle, Silke D and Perkhofer, Lukas and Ettrich, Thomas J and Kestler, Hans A},
  title = {Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0304324}
}
Kostenlos starten →